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Abstract
I In nt tr ro od du uc ct ti io on n: :   Early atherosclerotic changes in the endothelium associated with
metabolic syndrome are generated with the participation of inflammatory cells,
cytokines and enzymes of the extracellular matrix. The study is aimed at
a comparison between the activity of inflammatory agents, tumour necrosis
factor ʱ (TNF-ʱ) and the enzymes of the connective tissue matrix in the blood of
healthy female patients as well as those suffering from the metabolic syndrome.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The examination included 35 women with metabolic
syndrome (MS). The control group (C) comprised 35 healthy women. Lipidogram,
C-reactive  protein  level  (CRP),  fasting  glucose  level  (FGL),  matrix  metal  -
loproteinase (MMP)-8 and -9 activity, tissue inhibitor of metalloproteinase-1
(TIMP-1) and TNF-ʱ levels in blood were determined.
R Re es su ul lt ts s: :   As compared with the control group, the level of inflammatory factors
and the activity of extracellular matrix enzymes in the metabolic syndrome were
statistically higher (p < 0.05) and concerned the following parameters: TNF-ʱ
(pg/ml): MS 6.59 ±3.18, C 4.78 ±2.91; CRP (mg/dl): MS 2.18 ±2.04, C 1,26 ±1.35;
TIMP-1 (ng/ml): MS 265.5 ±2.9, C 205.4 ±72.6; MMP-9 (ng/ml): MS 198.2 ±138.6,
C 138.6 ±116.1. Statistically significant correlations were also found between
TIMP-1 and the following factors: BMI (R = 0.400, p < 0.001), waist/hip ratio
(WHR) (R = 0.278, p < 0.05), waistline (R = 0.417, p < 0.001), FGL (R = 0.290, 
p < 0.05), HDL cholesterol (R = –0.253, p < 0.05) and triglycerides (R = 0.269, 
p < 0.05).There were positive correlations of MMP-9 with FGL (R = 0.446, 
p < 0.001) and waistline (R = 0.260, p < 0.05); MMP-8 with FGL (R = 0.308, 
p < 0.05); and CRP with BMI (R = 0.370, p < 0.01), WHR (R = 0.325, p < 0.01) and
waistline (R = 0.368, p < 0.01).
C Co on nc cl lu us si io on ns s: :   Metabolic syndrome is connected with higher activity of cytokines
(TNF-ʱ), inflammatory markers (CRP) and matrix enzymes (MMP-9, MMP-8,
TIMP-1). 
K Ke ey y   w wo or rd ds s: :   metalloproteinase, tissue inhibitors of metalloproteinases, cytokines,
metabolic syndrome, atherosclerosis.
Introduction 
Risk factors contributing to the metabolic syndrome (disorders of lipid
and carbohydrate metabolism, obesity, arterial hypertension) may partici  -
pate in the development of atherogenesis. These coronary artery disease
risk factors can have an impact on the activity of connective tissue matrix.
The  enzymes,  in  turn,  are  responsible  for  the  metabolism  and
degradation of connective tissue. The major role in the inflammatory
process of atherosclerosis is played by the endo  thelium, extracellular
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Jolanta Mieczkowska
Chair and Department
of Internal Medicine
Medical University of Lublin
SPSK Nr 1
16 Staszica
20-081 Lublin, Poland
Phone/fax: +48 81 532 77 17
E-mail: jo.mie@poczta.onet.pl
Clinical research
1Chair and Department of Internal Medicine, Medical University of Lublin, Poland
2Students' Scientific Association of Department of Medical University of Lublin, Poland
S Su ub bm mi it tt te ed d: :   20 November 2009
A Ac cc ce ep pt te ed d: :   24 March 2010
Arch Med Sci 2011; 7, 4: 634-641
DOI: 10.5114/aoms.2011.24133
Copyright ﾩ 2011 Termedia & BanachArch Med Sci 4, August / 2011 635
matrix, and inflammatory cells of vascular smooth
muscle [1-3].
The first papers on the participation of matrix in
the pathogenesis of atherosclerosis were published
by Comejo et al. [4]. Metalloproteinases are factors
which regulate the composition of extracellular
matrix; they degrade the majority of its components
and basement membranes, and they stimulate
cytokines/chemokines secreted by macrophages,
smooth muscle cells and active endothelial cells [5]. 
In the opinion of some authors, cardiovascular
risk factors correlate with the activity of metallo  -
proteinases and their inhibitors [6, 7]. Untreated
familial hypercholesterolaemia changes the activity
of cytokines and enzymes [8]. In hypertensive pa  -
tients, raised levels of metalloproteinase (MMP)-2,
MMP-9 and tissue inhibitor of metalloproteinase-1
(TIMP-1) compared with the control group were
described, which determined the matrix compo  -
sition and increase in collagen type I deposits at the
expense of other matrix components in the cell wall
[9]. Taking part in the inflammation, the MMP-TIMP
complexes regulate the arterial blood pressure by
influencing the cell wall tension; they participate in
generating aortic aneurysm and vascular rebuilding
and also in coagulation and angiogenesis processes
[10]. The increased MMP-2 and -9 activity may
accompany  hyperglycaemia  and  presence  of
diabetic microangiopathy [11, 12]. Lipid metabolism
is also connected with the activity of metallo  -
proteinases. In the studies on transgenic mice in
which  the  apolipoprotein  E  (ApoE)  gene  was
blocked, the influence of atherogenic diet and
macrophage-produced MMP-1 on the development
of atherosclerosis was investigated. Less advanced
atherosclerotic changes in the endothelium, lower
content of collagen and more beneficial effect on
extracellular matrix remodelling in the presence of
MMP-1 were observed [5]. Acute cardiovascular
episodes also proceed with the activation of matrix
enzymes within the atheromatous plaque [13]. 
The study aimed to compare the activity of the
inflammatory process and enzymes of connective
tissue  matrix  in  patients  suffering  from  the
metabolic syndrome without clinical manifestation
of atherosclerosis with that state occurring in
healthy women. 
Material and methods
Thirty-five women (mean age 51.4 ±4.4 years)
were qualified for the examination. In addition, they
suffered from the metabolic syndrome and fulfilled
the  following  criteria:  waistline  ≥ 80 cm  and
additionally 2 out of 4 cardiovascular risk fac  tors –
concentration  of  fasting  glucose  in  the  blood 
> 100 mg/dl, arterial pressure RR > 135/80 mmHg
(an average was taken from two measurements,
arterial blood pressure after rest was taken) or
hypertension diagnosed earlier, HDL cholesterol
concentration in blood (HDL) < 50 mg/dl, tri  gly  ce  -
rides (TG) concentration > 150 mg/dl (International
Diabetes Federation) (International Diabetes Fede  -
ration. www.idf.org, 2005) [14].
The control group included 35 healthy women,
comparable with respect to age (mean age 50.18 ±
4.14 years), without abdominal obesity and not
fulfilling the metabolic syndrome criteria. 
These groups were separated during the popu  -
lation research from Lubelszczyzna in Poland from
758  patients  participating  in  the  population
examination – chosen at random.
Criteria for exclusion from the study were as
follows: earlier diagnosed myocardial ischaemia,
earlier diagnosed cerebral stroke, heart failure,
peripheral  vessel  disease,  severe  organic  and
systemic  disease,  rheumatic  diseases,  using
hormone replacement therapy or any other form of
medication.  Until  now  changes  in  the  matrix
enzyme activity have been described in relation to
the converting enzyme blockers [15]. 
L La ab bo or ra at to or ry y   n no ot ta at ti io on ns s
To examine the levels of lipids and glucose, blood
samples were taken on an empty stomach after 
12 h of fasting into test tubes from the kit, specially
prepared for that purpose.
The lipidogram was measured using a direct
enzymatic method, bioMerieux kits and COBAS
INTEGRA 600 analyser. The producer’s instructions
were strictly followed. The serum was stored frozen
at –25°C.
To determine the levels of total cholesterol, the
enzymatic and colorimetric method was used. The
principle of the method was as follows: cholesterol
esterase  hydrolyses  cholesterol  esters  to  free
cholesterol and fatty acids. Cholesterol oxidase then
catalyses cholesterol oxidation to the form of
cholest-4-en-3-one and hydrogen peroxide. In the
presence of peroxidase, under the influence of
hydrogen  peroxide,  there  follows  oxidative
connection of phenol and 4-aminoantipyrine and
the production of red colouring of quinone imine
chromogen. The intensity of colouring is directly
proportional to the cholesterol concentration. The
determination  was  made  by  the  measure  of
absorption increase at wavelength of 512 nm. 
120-200 mg/dl were assumed as reference values
of total cholesterol in women.
In the automated method of direct serum HDL
cholesterol determination, polyethylene glycol (PEG)
modified enzymes and dextran sulfate were used.
Enzymes modified by PEG (cholesterol esterase and
oxidase) reveal a selective catalytic activity towards
lipoprotein fractions. Cholesterol esters undergo
quantitative decomposition into free cholesterol
and fatty acids under the influence of cholesterol
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esterase. In the presence of oxygen, cholesterol is
oxidised  by  oxidase  to  ∆4-cholestenone  and
hydrogen peroxide. The intensity of blue colouring
is directly proportional to HDL concentration in the
sample. Determination was made by the mea  -
surement of absorption increase at wavelength of
583 nm. Reference values of HDL cholesterol in
women were assumed as > 55 mg/dl.
Triglycerides – glycerol esters with 3 long chain
fatty acids were determined using an enzymatic
method. To obtain full hydrolysis of triglycerides to
glycerol, lipoprotein lipase from microorganisms
was used and then oxidation to dihydroxyacetone
and hydrogen peroxide was applied. The obtained
hydrogen peroxide reacts with 4-aminophenazone
and  4-chlorophenol  with  the  participation  of
peroxidase creating a red coloured compound. The
intensity  of  red  colouring  is  proportional  to
triglycerides concentration and can be measured
photometrically. The reference values of triglycerides
in women were assumed as < 200 mg/dl.
The level of LDL cholesterol was measured accord  -
ing to Friedewald’s formula (LDL cholesterol (mg/dl)
= total cholesterol (mg/dl) – HDL cholesterol (mg/dl)
– triglycerides (mg/dl)/5), taking into account the
limitations connected with a high (above 450 mg)
level of triglycerides (in one patient from the studied
group). The reference values of LDL cholesterol in
women were established as < 135 mg/dl.
The concentration of fasting glucose was deter  -
mined using the enzymatic method with glucose
oxidase and COBAS INTEGRA 600 analyser. Refe  -
rence values of fasting glucose were established as
60-100 mg/dl. 
Body  mass  index  (BMI)  and  waist-hip  ratio
(WHR) were calculated. The C-reactive protein (CRP)
in blood was examined employing the turbidimetric
quantitative method and using Konelab 301. The
principle of the method is the immunoturbidimetric
test enhanced with PEG particles. Human CRP
agglutinates  with  those  particles  coated  by
monoclonal antibodies against human CRP. The
obtained precipitate is turbidimetrically measured
in a Konelab 301 analyser, using the calibration
curve. The producer’s instructions were strictly
followed. The reference value for CRP is 0-5 mg/l. 
The levels of MMP-8, MMP-9, TIMP-1 and tumour
necrosis factor (TNF)-ʱ were determined by using
the immunological test and the ELISA method. 
Blood for examination was taken on an empty
stomach between 10.00 am and 1 pm into specially
prepared test tubes with EDTA as the anticoagulant
and centrifuged for 15 min at room temperature.
The plasma obtained during centrifugation was
then divided into samples and stored in a freezer
at ≤ –25°C.
The levels of MMP-9, MMP-8 and TIMP-1 were
determined  using  the  kits  of  R&D  Systems
(Minneapolis, MN 55413, USA): Quantikine Human
MMP-9 (total) Immunoassay (catalogue number
DTM 900), MMP-8 (total) Immunoassay (catalogue
number DTM 800), Human TIMP-1 Immunoassay
(catalogue  number  DTM  100),  Human  TNF-ʱ/
TNFSF1A Immunoassay (catalogue number DTA00C).
The producer’s instructions were strictly followed.
The immunoenzymatic tests were based on the
ELISA method. They are designed for quantitative
determination of MMP-9, MMP-8, TIMP-1, TNF-ʱ on
biological material. In each case the calibration
curve was made. The results were read using the
III universal Bio-Tek ELX 800 microplate reader.
The levels of MMP-9, MMP-8, and TIMP-1 were
expressed in ng/ml, and TNF-ʱ in pg/ml. The 
D-dimer level in blood was determined using the
immunofluorescent method and BIO-MERIEUX kit.
Roche reagents were used for examinations and
the results were read with a COBAS INTEGRA 400
analyser. The reference value for D-dimers was 
< 500 FEU/ml. 
The  fibrinogen  level  was  determined  using 
the  coagulation  method  and  SYSMEX  CA-560.
Reference values for fibrinogen were assumed as
200-400 mg/dl.
S St ta at te em me en nt t   o of f   e et th hi ic cs s
All the examinations were performed with the
written consent of the patients. Approval to perform
the  study  was  obtained  from  the  Bioethical
Commission of the Medical University of Lublin 
(KE-0254/184; 185/2006). 
S St ta at ti is st ti ic c   a an na al ly ys si is s
Results were subjected to statistical analysis
using the Statistica 5.0 computer program. Non  -
parametric Mann-Whitney U tests were used for the
statistical workout during the comparison of the
groups. Relationships between various para  meters
were studied using Spearman’s test and deter  -
mining the R correlation coefficient. The value of 
p < 0.05 was assumed as statistically significant. 
Results 
In the studied group there were 13 menstruating
women; the remaining 22 women were in the
postmenopausal period. In the control group there
were 12 menstruating women and the others were
in the postmenopausal period.
Table I shows the comparison of mean values of
BMI, WHR, waistline, lipid levels, fasting glucose
and arterial blood pressure in the studied women
with  metabolic  syndrome  and  those  from  the
control group. All the studied parameters were
significantly more unfavourable in the group of
women with metabolic syndrome compared with
the control group.
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Table II shows the comparison of mean blood
levels of MMP-8 and -9, TIMP-1, TNF-ʱ, and CRP in
the studied women with metabolic syndrome and
in those from the control group. The activities of
MMP-9  and  tissue  inhibitor  of  MMP-1  were
significantly higher in the group of women with
metabolic syndrome than in the control group. Also
CRP and TNF-ʱ in the blood serum of women with
metabolic syndrome were significantly higher than
those in the control group.
Table  III  shows  Spearman's  correlation
coefficient (R) for TNF-ʱ, MMP-9, MMP-8 and the
following factors: obesity indices (BMI, WHR,
waistline),  fasting  plasma  glucose  level,  lipi  -
dogram (TG, HDL cholesterol levels) and pulse
pres  sure.
Figure 1 shows Spearman's correlation coefficient
(R) for TIMP-1 and the following factors: obesity
indices  (BMI,  WHR,  waistline),  fasting  plasma
glucose level, TG and HDL cholesterol levels. 
P Pa ar ra am me et te er rs s M MS S, ,   a av ve er ra ag ge e   ± ±   S SD D C C, ,   a av ve er ra ag ge e   ± ±   S SD D V Va al lu ue e   o of f   p p
( (M Mi in ni im mu um m- -m ma ax xi im mu um m) ) ( (M Mi in ni im mu um m- -m ma ax xi im mu um m) )
BMI [kg/m2] 30.87 ±5.18 (24.8-51.0) 23.50 ±2.67 (17.97-30.60) < 0.0001
WHR 0.8696 ±0.0586 (0.70-0.97) 0.7874 ±0.0518 (0.63-0.84) < 0.0001
Waistline [cm] 100.31 ±13.53 (85.0-135.0) 77.51 ±8.34 (60.0-92.0) < 0.0001
TCh [mg/dl] 245.21 ±65.99 (165.0-493.0) 224.86 ±37.50 (145-239) 0.3130
LDL [mg/dl] 156.08 ±67.58 (76.0-404.0) 138.28 ±29.90 (91-239) 0.3650
HDL [mg/dl] 56.82 ±13.17 (34.0-86.0) 69.11 ±15.27 (44-103) 0.0017**
TG [mg/dl] 154.38 ±94.31 (42.0-455.0) 96.57 ±46.01 (42-225) 0.0024**
FGL [mg/dl] 95.77 ±15.20 (69.0-132.0) 86.29 ±11.26 (68.0-123.0) 0.0060**
RRs [mmHg] 149.43 ±19.20 (120-200) 134.71 ±21.32 (100-180) 0.0013**
RRd [mmHg] 93.43 ±11.68 (70-110) 85.1429 ±14.38 (60-110) 0.0100**
RRs-d [mmHg] 49.57 ±15.97 (30-100) 49.57 ±11.14 (30-80) 0.0337*
T Ta ab bl le e   I I. . Comparison of mean values of BMI, WHR, waistline, lipid levels, fasting glucose and arterial blood pressure
in the studied women with metabolic syndrome and those from the control group
p – level of statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001), SD – standard deviation, MS – patients with the metabolic syndrome, 
C – control group, BMI – body mass index (kg/m2), WHR – waist/hip ratio, ChL – total cholesterol levels, LDL – LDL cholesterol levels, HDL – HDL
cholesterol levels, TG – triglycerides, FGL – fasting plasma glucose level, RRs – systolic blood pressure, RRd – diastolic blood pressure, 
RRs-d – the difference between systolic and diastolic pressure (pulse pressure)
P Pa ar ra am me et te er rs s M MS S, ,   a av ve er ra ag ge e   ± ±   S SD D C C, ,   a av ve er ra ag ge e   ± ±   S SD D V Va al lu ue e   o of f   p p
( (M Mi in ni im mu um m- -m ma ax xi im mu um m) ) ( (M Mi in ni im mu um m- -m ma ax xi im mu um m) )
MMP-9 [ng/ml] 197.77 ±140.65 (34.10-658.30) 138.59 ±116.09 (24.50-501.20) 0.0196*
TNF-ʱ [pg/ml] 6.59 ±3.18 (1.503-12.99) 4.78 ±2.91 (0.5-12.99) 0.0230*
TIMP-1 [ng/ml] 265.46 ±77.35 (142.50-432.20) 205.42 ±72.64 (74.30-422.60) 0.0014**
MMP-8 [ng/ml] 12.89 ±7.65 (2.98-30.16) 12.6417 ±5.84 (4.38-23.64) 0.9860
CRP [mg/l] 2.15 ±2.01 (0.10-8.30) 1.29 ±1.30 (0.2-6.6) 0.0393*
T Ta ab bl le e   I II I. .   Comparison of mean blood levels of MMP-8, -9, TIMP-1, TNF-ʱ, CRP in the studied women with metabolic
syndrome and in those from the control group
MMP-8, MMP -9 – metalloproteinases 8 and 9, TNF-ʱ – human tumor necrosis factor-ʱ, TIMP-1 – tissue inhibitor of metalloproteinase, 
CRP – C-reactive protein, other abbreviations – see Tables I
P Pa ar ra am me et te er rs s B BM MI I W WH HR R W Wa ai is st tl li in ne e F FG GL L H HD DL L T TG G R RR Rs s- -d d
TNF-ʱ [pg/ml] 0.120 0.143 0.149 0.116 –0.203  0.075 –0.056
MMP-9 [ng/ml] 0.222 0.192 0.260* 0.446*** –0.134 0.166 0.031
MMP-8 [ng/ml] 0.126 –0.003 0.050 0.308* 0.152 0.119 –0.141
CRP [mg/l] 0.370** 0.325** 0.368** 0.155 –0.065 –0.096 0.130
T Ta ab bl le e   I II II I. .   Spearman's correlation coefficients between the serum levels in blood TNF-ʱ, CRP, MMP-9, MMP-8 and the
following factors: obesity indices (BMI, WHR, waistline), fasting plasma glucose level, lipidogram (TG, HDL cholesterol
levels) and pulse pressure
Abbreviations – see Tables I and II
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F Fi ig gu ur re e   1 1. . Spearman's correlation coefficient (R) for TIMP-1 and the following factors: obesity indices (BMI, WHR,
waistline), fasting plasma glucose level, triglycerides (TG) and HDL cholesterol levels
Abbreviations – see Tables I and II
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Obesity indices significantly positively correlated
with the levels of CRP and TIMP-1 in blood. Fasting
glucose level significantly influenced the activities
of MMP-8 and -9 and TIMP-1. The TIMP-1 was also
under the significant influence of increased level
of  triglycerides  and  reduced  level  of  HDL. 
The associations between TNF-ʱ, TIMP-1, MMP-8, 
MMP-9, CRP with systolic, diastolic pressure and
pulse pressure were statistically insignificant. 
Table IV shows comparison of mean D-dimer
values and fibrinogen levels in blood between
patients with metabolic syndrome and healthy
women. Both of them were significantly higher
among women with metabolic syndrome.
Discussion 
In the pathogenesis of atherosclerosis, a signi  -
ficant role is played by the inflammatory process of
the  vascular  wall.  In  this  case,  inflammatory
markers  such  as  CRP,  adhesion  molecules,
metalloproteinases and cytokines act as athero  -
sclerosis predictors [16]. In our study, the level of
inflammatory markers CRP and TNF-ʱ, agents of
the coagulation system activation and fibrinoly  -
sis  (D-dimers,  fibrinogen)  participating  in  the
inflammatory  process  of  atherosclerosis  were
higher in patients with the metabolic syndrome as
compared  with  healthy  women.  Cytokines
themselves, including TNF-ʱ, can both initiate and
worsen the inflammatory condition. The inflam  -
matory process is also worsened by the existence
of  other  factors  that  trigger  disorders  in  the
endothelial and vascular wall metabolism such as
hyperlipidaemia,  carbohydrate  disorders,  and
arterial hypertension [17, 18]. The multiple functions
of proinflammatory cytokines include activating the
matrix synthesis, increasing endothelial permea  -
bility, allowing lipid storage in vascular wall and
initiating proliferation of endothelial cells. The 
TNF-ʱ and interleukin IL-1 induce metalloproteinase
synthesis as well as curb the synthesis of tissue
inhibitors of metalloproteinase. In the inflammatory
process of atherosclerosis, mutual associations
between inflammatory cells, cytokines, chemokines
and lipids are of some importance [19-22]. 
The majority of connective tissue cells produce
both  metalloproteinases  and  their  inhibitors.
Curbing metalloproteinase activity is caused by
creating complex systems from active types of
metalloproteinases and their tissue inhibitors. The
TIMP-1 inactivates most MMPs [2].
In our study, the levels of both MMP-9 and the
TIMP-1  were  higher  among  patients  with  the
metabolic syndrome as compared with the control
group. Our findings were consistent with those of
other authors [23, 24]. Simultaneously, the activity
of these enzymes increased with greater intensity
of cardiovascular risk factors contributing to the
metabolic syndrome, including obesity, atherogenic
lipid profile and the concentration of fasting plasma
glucose in blood. The MMP-9, which downgrades
mainly collagen type IV [1], is more active among
patients with the metabolic syndrome. In our study,
this activity was associated with fasting plasma
glucose level (the highest correlation coefficient
was noted between MMP levels and fasting plasma
glucose level, whereas lower correlation coefficients
were noted between MMP-9 level and obesity
indices). Numerous publications have pointed to
a greater activity of metalloproteinase MMP-9 as
well as MMP-2 in type-2 diabetes [11]. This greater
activity  is  believed  to  be  connected  with
hyperglycaemia and diabetic microangiopathy [12].
Effective treatment of type 2 diabetes by using
rosiglitazone  reduces  MMP-9  activity  among
patients with simultaneously diagnosed myocardial
ischaemia [25]. Such data suggest that MMPs can
be regarded as a marker of atherosclerosis activity
[24]. In our studies, high correlation indices were
found  of  fasting  glucose  levels  not  only  with 
MMP-9 but also with MMP-8 and TIMP-1 levels in
blood.
The  development  of  vascular  changes  in
diabetes can be connected not only with increased
metalloproteinase activity but also with a disturbed
MMP/TIMP  ratio  [26,  27].  Our  study  showed
increased activity of the tissue inhibitor of MMP-1
among  patients  suffering  from  the  metabolic
syndrome as compared with the control group. This
activity changed with the intensity of cardiovascular
risk factors and was higher with increased values
of the following factors: obesity, abdominal obesi  -
ty, atherogenic lipid profile, and fasting plasma
glucose level. Similar results were noted by other
researchers  [10,  28].  In  the  examined  group,
E Ex xa am mi in ne ed d   g gr ro ou up ps s P Pa ar ra am me et te er rs s A Av ve er ra ag ge e   ± ±   S SD D   ( (m mi in ni im mu um m- -m ma ax xi im mu um m) ) V Va al lu ue e   o of f   p p
MS D-dimers [FEU/ml] 550.23 ±374.03 (170.4-1362.7) **
C D-dimers [FEU/ml] 295.39 ±276.70 (108.6-1162.0)
MS Fibrinogen [mg/dl] 431.25 ±88.58 (290.0-540.0) *
C Fibrinogen [mg/dl] 321.68 ±127.70 (53.0-500.0)
T Ta ab bl le e   I IV V. .   Comparison of mean D-dimer values and fibrinogen levels between patients with metabolic syndrome and
healthy women
Abbreviations – see Tables I and II
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a positive correlation between TIMP-1 activity and
numerous  cardiovascular  risk  factors  can  be
attributed to the protective role of TIMP-1 in relation
to factors degrading extracellular matrix (MMPs)
accompanied by hypertension, obesity and lipid
disorders. 
Similar to our study, epidemiological research
conducted by Głowińska-Olszewska [29], concern  -
ing children and teenagers, shows higher MMP-9
and TIMP-1 levels in the case of overweight, obesity
and arterial hypertension coexistence. Increased
activity of MMP-9, TIMP-1 and MMP-2 among
patients with arterial hypertension has also been
observed by other authors [30, 31]. The effective
treatment of arterial hypertension has, in turn,
caused lower activity of MMP-9 and increased
activity of tissue inhibitor of metalloproteinase
TIMP-1 [9, 15].
Among the examined patients, an increase in
obesity indices (waistline) was accompanied by an
increased activity of MMP-9. Nevertheless, cor  re  la  -
tion  coefficients  between  MMS-8  and  obesity
indices were lower. According to the data found in
the literature, metalloproteinase-8 is an enzyme
degrading collagen type 1 which forms athero  -
matous plaque. The MMP-8 can participate in the
development of severe coronary condition caused
by a fracture of the atheromatous plaque [32-34].
Moreover,  together  with  MMP-9,  MMP-8  can
contribute  to  the  development  of  a fractured
aneurysm of large arterial vessels [35]. 
The associations between metalloproteinase
activity and cardiovascular risk factors suggest that
the activity of connective tissue matrix enzymes
increases when an inflammatory atherosclerotic
process is in progress in the vascular wall. So far,
the research conducted on this subject makes it
reasonable  to  conclude  that  some  medicines
affecting cardiovascular risk factors (rosiglitazone,
inhibitors of the converting enzyme) decrease the
activity of matrix enzymes [15, 25]. 
Metabolic syndrome concerns women at every
age  although  it  more  frequently  occurs  after
menopause.  Our  studied  group  of  pre-  and
postmenopausal women is not numerically big;
however, it was randomly selected from among 758
participants  of  population  studies  of  the
Lubelszczyzna region.
The future will tell whether the atherosclerotic
process can be monitored by marking the activity
of matrix enzymes; the issue requires further
studies of larger populations.
In conclusion, the activity of factors participating
in the inflammatory atherosclerotic process of the
vascular  wall  is  higher  in  patients  with  the
metabolic syndrome as compared with healthy
women. These factors include cytokines (TNF-ʱ),
the coagulation system and fibrinolysis (D-dimers,
fibrinogen), enzymes of connective tissue matrix
(MMP-9, TIMP-1) and markers of inflammation
(CRP).
The higher the intensity of cardiovascular risk
factors, the greater the activity of matrix enzymes
in blood serum. The MMP-9 activity increases with
the fasting plasma glucose level. The TIMP-1 activity
increases with higher obesity indices, atherogenic
lipid profile and fasting glucose level. The MMP-8
activity increases with fasting glucose level. 
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